Novo Nordisk delivered better-than-expected results in Q1 19, both at the top-line as well as bottom-line. However, some one-offs had a role to play in this. The profit beat was, to a large extent, driven by a reversal of inventory write-down, although completion of some key trials also boosted the margins. We continue to expect the diabetes market to get tougher to operate in and the FDA verdict on oral Semaglutide to be the next big trigger for Novo Nordisk.
03 May 2019
Beat driven by some one-offs
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Beat driven by some one-offs
Novo Nordisk A/S Class B (NNO2:WBO) | 0 0 2.2% | Mkt Cap: 611,927m
- Published:
03 May 2019 -
Author:
Kamla Singh -
Pages:
3
Novo Nordisk delivered better-than-expected results in Q1 19, both at the top-line as well as bottom-line. However, some one-offs had a role to play in this. The profit beat was, to a large extent, driven by a reversal of inventory write-down, although completion of some key trials also boosted the margins. We continue to expect the diabetes market to get tougher to operate in and the FDA verdict on oral Semaglutide to be the next big trigger for Novo Nordisk.